<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> (GLP-1 RA) are used for treatment in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>Little is known about their cardiovascular (CV) impact </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine the effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment on vascular function in T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>Brachial artery endothelial-dependent flow-mediated dilation (FMD) and endothelial-independent <z:chebi fb="2" ids="24364">glyceryl</z:chebi> trinitrate (GTN) function and carotid intima-medial thickness (cIMT) were assessed in 11 severely <z:mp ids='MP_0001261'>obese</z:mp> T2DMs (4 females, 7 males: 55 ± 8 years, <z:mp ids='MP_0002055'>diabetes</z:mp> duration 8.3 ± 4.7 years mean ± s.d.) before and after 6 months GLP-1 RA </plain></SENT>
<SENT sid="4" pm="."><plain>Body weight (5.3 ± 1.2 kg; p &lt; 0.05) and magnetic resonance imaging determined total and subcutaneous fat, but not visceral fat, decreased </plain></SENT>
<SENT sid="5" pm="."><plain>Glycaemic control improved </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant changes in FMD, GTN and cIMT (-1.1 ± 0.4%, 0.3 ± 3.0% and 0.00 ± 0.04 mm, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Despite significant improvements in body composition and glycaemic control, 6 months GLP-1 RA treatment did not modulate vascular function </plain></SENT>
<SENT sid="8" pm="."><plain>Alternative strategies may therefore be needed to reduce the burden of CV risk in severely <z:mp ids='MP_0001261'>obese</z:mp> patients with long-standing T2DM </plain></SENT>
</text></document>